| Patient | Ray Charles |
|---|---|
| Date of birth | 1960-09-23 |
| Identifiers | MRN HR-ML009-SYN; SSN (made up) 000-09-5561 |
| Document date | 2026-03-31 |
| Author | Gloria Fenwick, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week follow-up, seen the same day by ophthalmology for the blind eyes. [S]
Mr. Charles is a 65-year-old man, blind since childhood, with an opioid use disorder in sustained remission for more than thirty years, who returns four weeks after his first visit and is seen by ophthalmology on the same day. His eyes have been comfortable, with no pain, redness, discharge, or headache around the eyes. He picked up the naloxone nasal spray; the pharmacy put a braille label on the box and now gives audio labels for any medicine. He received his first-visit summary and results as an accessible electronic document and read them with his screen reader. He has had no opioid or other drug use and no cravings, and he has been touring as usual. He has had no falls. [S]
| Element | Detail |
|---|---|
| Eyes | Comfortable; no pain, redness, or discharge |
| Recovery | No use and no cravings |
| Naloxone | Dispensed with a braille label |
| Accessibility | Visit summary received and read with his screen reader |
| Falls | None |
| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No eye pain, redness, discharge, or headache around the eyes |
| Psychiatric | Negative | Mood good; no cravings; no thoughts of suicide or self-harm |
| Musculoskeletal | Negative | No falls, joint pain, or back pain |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response, and call 911 | Nasal route | 2026-03-03 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-31 | Body height | 178 | cm | S |
| 2026-03-31 | Body weight | 80.2 | kg | S |
| 2026-03-31 | Body mass index (BMI) [Ratio] | 25.3 | kg/m2 | S |
| 2026-03-31 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-03-31 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-31 | Heart rate | 66 | /min | S |
| 2026-03-31 | Respiratory rate | 14 | /min | S |
| 2026-03-31 | Body temperature | 36.6 | Cel | S |
| 2026-03-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 2026-03-31; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert, warm, and witty. Each step of the examination described before it was done |
| Eyes | No light perception. Lids and ocular surfaces quiet, with no redness, swelling, or discharge; ophthalmology examined him today |
| Psychiatric | Euthymic; organized thought; no signs of intoxication or withdrawal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blindness of both eyes since childhood, no light perception; cause never diagnosed | active | confirmed | H54.0X55 | S — Synthetic modern coding of the documented childhood blindness; category 5 (no light perception) is a synthetic grading of what the sources call blindness. |
| Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatment | active | confirmed | F11.21 | S — Synthetic modern coding of the publicly admitted heroin addiction and his documented recovery; listed as an active problem because it is managed at every visit, with remission carried by the code. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Comprehensive eye examination | Yearly for blind eyes, or with symptoms | Completed today | Ophthalmology examination today: no light perception; quiet, comfortable eyes; no active disease |
| Examination | Eye comfort and ocular surface check: pain, redness, discharge | Every visit | Completed today | No pain, redness, or discharge; ocular surfaces quiet |
| Examination | Tonometry (eye pressure) | Every glaucoma visit; for blind eyes, only if pain or redness | Not indicated | No light perception and no pain; ophthalmology advises measuring only if pain or redness develops, because lowering pressure cannot help vision |
| Imaging | OCT, optic disc imaging, and visual fields | Every 6 to 12 months in sighted glaucoma | Not indicated | Not informative without light perception |
| Examination | Gonioscopy and central corneal thickness | At baseline in glaucoma | Not indicated | Would not change care in blind, painless eyes |
| Medication safety | Eye-drop adherence and side effects | Every visit | Not indicated | No eye drops |
| Self-management | Teaching about eye red flags (pain, redness, headache around the eye) | At diagnosis and each eye visit | Completed today | He knows to seek same-day care for eye pain, redness, discharge, or headache around the eye |
| Survey | Depression screen (PHQ-9) | At intake, at six months, and yearly | Up to date | PHQ-9 2 four weeks ago; mood good today |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; the 988 Suicide & Crisis Lifeline is saved in his phone |
| Survey | Mood Disorder Questionnaire | At a new depressive episode | Not indicated | No depressive episode |
| Self-management | Recovery check: any return to use, cravings, triggers, and supports | Every visit | Completed today | No return to use and no cravings; work and long-time friends remain his supports |
| Medication safety | Naloxone at home and when traveling | At intake; check expiry at each visit | Completed today | Dispensed with a braille label; one for home and one for travel |
| Survey | Drug-use screen (DAST-10) | Yearly | Up to date | DAST-10 0 four weeks ago |
| Survey | Alcohol screen (AUDIT-C) | Yearly | Up to date | AUDIT-C 2 four weeks ago |
| Laboratory | Hepatitis C, hepatitis B, and HIV testing | At entry to care for a person with a substance use disorder | Deferred | Not offered at intake, a deviation from the VA/DoD guidance. He has no symptoms, so no harm is evident. Corrective action: hepatitis C, hepatitis B, and HIV testing to be drawn with his consent at the annual wellness visit, together with the Medicare preventive tests |
| Medication safety | Medication for opioid use disorder | Offered to every person with active opioid use disorder | Not indicated | Sustained remission for more than thirty years without medication; he knows that buprenorphine and methadone are available if he ever needs them |
| Laboratory | Urine drug testing | During treatment for active opioid use disorder | Not indicated | Not used in long sustained remission without treatment; it would add nothing and could feel stigmatizing |
| Self-management | Written plan for any future acute pain or surgery | Before any planned procedure, and once in remission | Due | To be written with him at the next visit |
| Self-management | Accessible documents and communication | Every visit | Completed today | Spoken orientation and description of each step; visit summary sent as an accessible electronic document |
| Medication safety | Medicine labeling in braille or audio | With every new prescription | Completed today | Braille label on the naloxone; audio labels from the pharmacy |
| Examination | CDC STEADI fall-risk screen | Every visit from age 65 | Completed today | No falls; steady gait; Timed Up and Go 10 seconds four weeks ago |
| Referral | Ophthalmology consultation | Once, then yearly | Completed today | Seen today |
| Referral | Vision rehabilitation services (orientation and mobility, assistive technology) | Offered to anyone with vision loss, and again with any change | Completed today | Offered by ophthalmology today; he has long-established skills and does not want them now |
| Self-management | Advance care planning | Yearly from age 65 | Due | At the annual wellness visit in the autumn |
| Self-management | Vaccinations | Yearly, per the CDC schedule | Due | Influenza vaccine given last autumn; others reviewed at the annual wellness visit |
Goal progress:
Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Primary Open-Angle Glaucoma Preferred Practice Pattern (2025); Vision Rehabilitation Preferred Practice Pattern (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, glaucoma and depression, bipolar, and mood disorders monographs (2026)
Follow-up: Three-month review. Same-day visit for eye pain or redness. Yearly ophthalmology review. Next scheduled visit 2026-06-02: three-month review of recovery, accessibility, and fall prevention. [S]